Discovery of ErbB/HDAC inhibitors by combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib, BMS-690514, neratinib, and TAK-285

By merging the critical pharmacophore of kinase and HDAC inhibitors into one compound, a novel series of 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety were synthesized as ErbB and HDAC dual-targeted inhibitors.